Status:
COMPLETED
Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment
Lead Sponsor:
GlaxoSmithKline
Conditions:
Osteoporosis, Postmenopausal
Eligibility:
FEMALE
18+ years
Brief Summary
Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate treatment
Detailed Description
Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in Korean postmenopausal osteoporosis patients with bisphosphonate treatment
Eligibility Criteria
Inclusion
- Who have been diagnosed with postmenopausal osteoporosis by physician Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire Who provide informed consent for study participation
Exclusion
- Do not understand the contents of the questionnaire
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
4376 Patients enrolled
Trial Details
Trial ID
NCT01227369
Start Date
June 1 2008
End Date
November 1 2009
Last Update
June 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Seoul, South Korea, 137-701